Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07771465 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of the Long-term Safety and Efficacy of Danicamtiv in Adults With Symptomatic Genetic and Familial Dilated Cardiomyopathy

Study acronym: KINSHIP-OLE
StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Eligibility criteria expanded, about 8 words
    • Secondary endpoints: details revised at 3 of 6 entries
    • Site details revised at 9 of 78 sites
    • Study description expanded, about 2 words
  2. Recruitment opened
    • Start date changed from estimate of Aug 2026 to Aug 26, 2026
    • Site details revised at 78 of 78 sites
    v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Danicamtiv is an investigational medication, which means it is still being studied and has not been approved. The purpose of this study is to learn how well danicamtiv works, how safe it is, how well people can take it when used in patients with genetic or familial dilated cardiomyopathy (DCM). There are currently no approved medicines made specifically to treat genetic or familial DCM.
Trial Details
NCT Number NCT07771465
Lead Sponsor Kardigan, Inc.
Conditions
(from sponsor)		 Symptomatic Genetic Dilated Cardiomyopathy (DCM)
Enrollment 332 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov